Andere Sprachen Ionis Pharmaceuticals, Inc.

Aktien

A2ACMZ

US4622221004

IONS

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 07.06.2024			% 5 Tage	% 1. Jan.
38,95 ^USD	-2,31 %		+3,67 %	-23,01 %

06.06.	Transcript : Ionis Pharmaceuticals, Inc. - Special Call
31.05.	Ionis meldet "positive Ergebnisse" aus Studien zu einem Prüfpräparat zur Behandlung des hereditären Angioödems	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Ionis Pharmaceuticals : Login Information	06.06.
Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema	03.06.
Ionis Pharmaceuticals : Donidalorsen Ph3 Data EAACI'24 Webcast Slides	31.05.
Ionis Reports 'Positive Results' From Studies of Investigational Treatment for Hereditary Angioedema	31.05.
Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema	31.05.
Ionis Pharmaceuticals, Inc. Presents Positive Results from OASIS-HAE and OASISplus Studies of Investigational Medicine Donidalorsen in Patients with Hereditary Angioedema	31.05.
Ionis to hold donidalorsen Phase 3 data webcast	28.05.
New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA)	23.05.
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	16.05.
Sector Update: Health Care Stocks Ease Thursday Afternoon	16.05.
US Equity Indexes Trade Mixed as Investors Weigh Macro Data; Dow Touches Record High	16.05.
Sector Update: Health Care	16.05.
Dow Touches 40,000 Mark for First Time as Macroeconomic Data Signals Economic Weakness	16.05.
Ionis Pharmaceuticals Says Potential Angelman Syndrome Therapy Improves Symptoms in Phase 1/2a Study	16.05.
Stocks in motion: Walmart, Chubb, Deere...	16.05.
Sector Update: Health Care Stocks Steady Premarket Thursday	16.05.
Biogen, Ionis to Cease BIIB105 ALS Investigational Drug Development Following Phase 1/2 Trial Results	16.05.
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis	16.05.
Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome	16.05.
Ionis to host 2024 virtual Annual Meeting of Stockholders	15.05.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Ionis Pharmaceuticals, Inc.

Aktien

A2ACMZ

US4622221004

IONS

Andere Sprachen

Filter